SRGN was also mildly expressed in bone-metastatic breast cancer cell lines SCP2 and 1833 [36], but not in normal bone stroma cells including mesenchymal stem cells, osteoblasts and osteoclasts (Supplementary Fig. S1E). Here, SRGN is linked to breast cancer.